Reistone Biopharma’s Ivarmacitinib Meets its Primary Endpoint in P-III (QUARTZ3) Trial for the Treatment of Atopic Dermatitis
Shots:
- The P-III (QUARTZ3) trial evaluating ivarmacitinib (8/4mg) as monothx. vs PBO in 336 adult & adolescent patients with AD at 15 research centers in Canada & 36 in China. Ivarmacitinib (JAK1 inhibitor) was developed by Reistone & Jiangsu Hengrui for oral use
- The trial met its co-primary EPs i.e., improvement in IGA 0/1 response rate and EASI 75 response rate @16wk. The therapy was well-tolerated at both doses without new safety findings
- The results also showed that the optimal efficacy trend was consistent with the general population. The therapy is currently being studied in multiple ongoing late-stage trials with oral & topical dosage forms for multiple immune-inflammatory diseases incl. UC, Alopecia Areata, CD
Ref: PRNewswire | Image: Reistone Biopharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
